Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BONNIE S GLISSON and RENATA FERRAROTTO.
BONNIE S GLISSON
Connection Strength
5.438
RENATA FERRAROTTO
  1. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90.
    View in: PubMed
    Score: 0.663
  2. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Curr Opin Oncol. 2016 May; 28(3):195-200.
    View in: PubMed
    Score: 0.576
  3. Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2023 Jul 14; 29(14):2737.
    View in: PubMed
    Score: 0.237
  4. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851.
    View in: PubMed
    Score: 0.231
  5. Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncol. 2023 03; 138:106311.
    View in: PubMed
    Score: 0.229
  6. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
    View in: PubMed
    Score: 0.217
  7. Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report. J Intensive Care Med. 2022 Aug; 37(8):1055-1059.
    View in: PubMed
    Score: 0.211
  8. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022 02 01; 128(3):509-518.
    View in: PubMed
    Score: 0.210
  9. Therapeutic approaches and outcomes in patients with larynx or hypopharynx high-grade neuroendocrine carcinoma: A single-center retrospective analysis. Head Neck. 2021 12; 43(12):3788-3795.
    View in: PubMed
    Score: 0.209
  10. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591.
    View in: PubMed
    Score: 0.206
  11. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
    View in: PubMed
    Score: 0.206
  12. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2021 02 01; 27(3):852-864.
    View in: PubMed
    Score: 0.197
  13. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res. 2020 07 01; 26(13):3211-3219.
    View in: PubMed
    Score: 0.189
  14. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020 02; 101:104523.
    View in: PubMed
    Score: 0.185
  15. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):67-73.
    View in: PubMed
    Score: 0.173
  16. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck. 2018 08; 40(8):1676-1684.
    View in: PubMed
    Score: 0.164
  17. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
    View in: PubMed
    Score: 0.150
  18. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1674-1686.
    View in: PubMed
    Score: 0.140
  19. New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic. Clin Cancer Res. 2015 Sep 01; 21(17):3821-8.
    View in: PubMed
    Score: 0.137
  20. Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung. Curr Oncol Rep. 2023 01; 25(1):1-10.
    View in: PubMed
    Score: 0.057
  21. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022 02; 10(2).
    View in: PubMed
    Score: 0.054
  22. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420.
    View in: PubMed
    Score: 0.052
  23. Role of induction chemotherapy for oral cavity squamous cell carcinoma. Cancer. 2021 09 01; 127(17):3107-3112.
    View in: PubMed
    Score: 0.051
  24. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer. 2021 08 15; 127(16):2916-2925.
    View in: PubMed
    Score: 0.051
  25. The tumor immune contexture of salivary duct carcinoma. Head Neck. 2021 04; 43(4):1213-1219.
    View in: PubMed
    Score: 0.050
  26. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
    View in: PubMed
    Score: 0.050
  27. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
    View in: PubMed
    Score: 0.050
  28. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245.
    View in: PubMed
    Score: 0.050
  29. High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Ann Diagn Pathol. 2020 Dec; 49:151622.
    View in: PubMed
    Score: 0.049
  30. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463.
    View in: PubMed
    Score: 0.048
  31. Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiother Oncol. 2020 07; 148:258-266.
    View in: PubMed
    Score: 0.048
  32. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.047
  33. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg. 2019 Jul/Aug; 35(4):350-353.
    View in: PubMed
    Score: 0.045
  34. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol. 2019 02 20; 37(6):504-512.
    View in: PubMed
    Score: 0.043
  35. PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. Head Neck. 2019 03; 41(3):615-622.
    View in: PubMed
    Score: 0.043
  36. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019 06; 103(6):775-780.
    View in: PubMed
    Score: 0.042
  37. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017 Dec; 77(6):1110-1113.e2.
    View in: PubMed
    Score: 0.040
  38. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017 08; 39(8):1671-1679.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.